BTIG analyst Ryan Zimmerman upgraded Treace Medical (TMCI) to Buy from Neutral with a $16 price target The company has pivoted away from ...

Concepts Inc (NASDAQ:TMCI) received an upgrade from BTIG, with analyst Ryan Zimmerman changing the stock rating from Neutral to Buy and setting a new price target of $16.00. This upgrade comes after a ...

BTIG analyst Ryan Zimmerman upgraded Treace Medical Concepts (TMCI – Research Report) to a Buy today and set a price target of $16.00. The ...

Treace Medical Concepts, Inc.’s TMCI share price has surged by 10.21%, which has investors questioning if this is right time to sell.

PONTE VEDRA, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in ...

Treace Medical Concepts, Inc. TMCI recently announced the limited market release and first surgical cases utilizing the Percuplasty Percutaneous 3D Bunion Correction System and Procedure.

Treace Medical Concepts, Inc. PONTE VEDRA, Fla., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company ...

Shares of Treace Medical Concepts, Inc. (NASDAQ:TMCI – Get Free Report) have received a consensus rating of “Hold” from the seven research firms that are covering the stock, Marketbeat reports.

Treace Medical Concepts Trading Up 5.6 % NASDAQ TMCI opened at $8.71 on Friday. Treace Medical Concepts, Inc. has a one year low of $3.92 and a one year high of $15.98. The firm has a market cap ...

Short interest in Treace Medical Concepts Inc (NASDAQ:TMCI) decreased during the last reporting period, falling from 2.38M to 2.32M. This put 4.77% of the company's publicly available shares short.